This study will measure the safety and tolerability of three different doses of IdB 1016 in
patients with hepatitis C disease who have not responded to or are poor candidates for
interferon-based therapies.
NOTE: THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL
CENTER IN SEATTLE
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)